N-[2,4-difluoro-3-(2-pyrazolo[1,5-a]pyrimidin-6-ylethynyl)phenyl]pyridine-3-sulfonamide
C19H11F2N5O2S — CID 122179525
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[2,4-difluoro-3-(2-pyrazolo[1,5-a]pyrimidin-6-ylethynyl)phenyl]pyridine-3-sulfonamide
N-[2,4-difluoro-3-(2-pyrazolo[1,5-a]pyrimidin-6-ylethynyl)phenyl]pyridine-3-sulfonamide (PubChem CID 122179525) has the molecular formula C19H11F2N5O2S and a molecular weight of 411.39 g/mol. Its IUPAC name is N-[2,4-difluoro-3-(2-pyrazolo[1,5-a]pyrimidin-6-ylethynyl)phenyl]pyridine-3-sulfonamide.
Molecular Properties
| Compound Name | N-[2,4-difluoro-3-(2-pyrazolo[1,5-a]pyrimidin-6-ylethynyl)phenyl]pyridine-3-sulfonamide |
|---|---|
| PubChem CID | 122179525 |
| Molecular Formula | C19H11F2N5O2S |
| Molecular Weight | 411.39 g/mol |
| Exact Mass | 411.06 |
| IUPAC Name | N-[2,4-difluoro-3-(2-pyrazolo[1,5-a]pyrimidin-6-ylethynyl)phenyl]pyridine-3-sulfonamide |
| SMILES | O=S(=O)(Nc1ccc(F)c(C#Cc2cnc3ccnn3c2)c1F)c1cccnc1 |
| InChI | InChI=1S/C19H11F2N5O2S/c20-16-5-6-17(25-29(27,28)14-2-1-8-22-11-14)19(21)15(16)4-3-13-10-23-18-7-9-24-26(18)12-13/h1-2,5-12,25H |
| InChIKey | CBGJZIAUYLUGFE-UHFFFAOYSA-N |
| XLogP | 2.60 |
| TPSA | 89.25 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 411.39 |
| LogP ≤ 5 | 2.60 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'triple_bond', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122179525 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.